Investment Rating - The report recommends a "Buy" rating for multiple companies in the pharmaceutical sector, including Junshi Biosciences, Hualan Biological Engineering-B, and others [3]. Core Insights - The pharmaceutical sector has shown a 1.90% increase this week, outperforming the CSI 300 index by 0.21 percentage points. Sub-sectors such as pharmaceutical outsourcing, vaccines, and medical consumables performed well, while innovative drugs lagged behind [6][42]. - The report emphasizes the potential of the 4-1BB target in cancer treatment, particularly the PD-L1/4-1BB bispecific antibodies, which may address the limitations of PD-1/PD-L1 monotherapy [5][16][17]. Summary by Sections Industry Viewpoints and Investment Recommendations - 4-1BB is recognized as a promising target for tumor therapy, enhancing T cell activation and survival, which is crucial for effective immune responses against cancer [16]. - Investment strategies focus on the innovative drug sector, driven by increased liquidity and risk appetite, with a recommendation to pay attention to companies with strong pipelines in bispecific antibodies and ADCs [6][38]. Pharmaceutical Industry Market Performance - The pharmaceutical sector's overall P/E ratio is reported at 30.67 times, with a premium of 40.37% compared to the overall A-share market excluding financials [42]. Company Dynamics - Notable company developments include: - LIZHU Group's successful Phase III trial for a monoclonal antibody for psoriasis [43]. - Baiyang Pharmaceutical's planned share reduction by its major shareholder [43]. - Mylab's new medical device approval, enhancing market competitiveness [44]. Industry Dynamics - The report highlights the increasing focus on innovative drug development and the potential for significant market opportunities in the context of upcoming patent expirations for key small molecule drugs [38].

Group 1: Internet Media - Google's advertising revenue exceeded expectations in Q2 2025, indicating overall active economic activity in the U.S. and alleviating concerns about AI's impact on traditional search engine advertising [2] - Google Cloud's revenue and profitability were strong, leading to an upward revision of the annual capital expenditure guidance, with AI demand continuing to outstrip supply [2] - The full-stack AI industry chain comprising data centers, ASICs, algorithms, and products gives Google a solid and differentiated advantage in the AI field, suggesting continued attention is warranted [2] Group 2: Petrochemicals - The Ministry of Industry and Information Technology is set to launch a growth stabilization plan for the petrochemical industry, which is expected to promote the elimination of outdated capacity and lead to healthier industry development [3] - Key companies to watch include: in the soda ash sector, Boyuan Chemical, Shandong Haihua, China Salt Chemical, and Shuanghuan Technology; in the PVC sector, Xinjiang Tianye, Sanyou Chemical, and Chlor-alkali Chemical [3] Group 3: Non-ferrous Metals - The recent Central Financial Committee's emphasis on legally governing low-price disorderly competition is expected to facilitate the orderly exit of outdated capacity in the copper smelting industry [4] - If the "anti-involution" theme is implemented, it may limit new copper smelting capacity and accelerate the exit of small smelting capacities, leading to improved profitability for smelting enterprises [4] - Companies to focus on include Tongling Nonferrous Metals, China Daye Nonferrous Metals, Jiangxi Copper, and Yunnan Copper [4] Group 4: Construction - The commencement of the Yajiang Hydropower Station is expected to generate new demand for construction and materials [5] - Recommended companies include China Power Construction, China Energy Construction, China Communications Construction, and China Railway, along with material suppliers like Huaxin Cement and Tibet Tianlu [5] Group 5: Pharmaceuticals - The precise adjustment of medical insurance policies is reshaping the pharmaceutical industry ecosystem, with the "anti-involution" in procurement clearing low-quality capacity and creating market space for quality enterprises [6] - Focus on two types of companies: those that continue to be selected in procurement with dual advantages in quality and cost, and innovative drug companies with rich R&D pipelines [6] - Recommended companies include Heng Rui Medicine, Jingxin Pharmaceutical, and Jiuzhou Pharmaceutical, with attention to MicroPort Medical, Zhongsheng Pharmaceutical, and Fangsheng Pharmaceutical [6] Group 6: Automotive - Tesla's Q2 2025 performance showed a recovery, with a shift in focus towards AI-driven initiatives like Robotaxi and humanoid robots [8] - Due to uncertainties in overseas policies and market sales, the 2025E/2026E/2027E Non-GAAP net profit estimates have been adjusted to $6.06 billion, $8.77 billion, and $11.28 billion respectively [8] - Tesla's leading position in AI technology iteration and commercialization capabilities remains a positive outlook [8] Group 7: Internet Literature - The online reading business of the report's subject company remains stable, but revenue forecasts for 2025-2027 have been revised down to 7.39 billion, 7.95 billion, and 8.14 billion yuan due to uncertainties in new series and adjustments in short drama revenue recognition [9] - The company's proprietary profit continues to improve, supported by the strong performance of new businesses like short dramas and IP derivatives [9] - The full-year performance growth remains highly certain, with adjusted net profit forecasts of 1.35 billion, 1.53 billion, and 1.66 billion yuan for 2025-2027 [9]

2025 年 07 月 20 日 投资评级：看好（维持） 医药生物 行业走势图 -24% -12% 0% 12% 24% 36% 2024-07 2024-11 2025-03 医药生物 沪深300 数据来源：聚源 相关研究报告 《CXO 龙头中报业绩超预期，重点关 注板块后续行情 — 行 业 周 报 》 -2025.7.13 《艾伯维收购 Capstan，加码体内 CAR-T—行业周报》-2025.7.6 《多款减肥药亮相 2025 ADA，重点关 注 AMYR 与 ActRII 靶点—行业周报》 -2025.6.29 集采政策明确优化，继续推荐制药板块性机会 ——行业周报 | 余汝意（分析师） | 刘艺（联系人） | 聂媛媛（联系人） | | --- | --- | --- | | yuruyi@kysec.cn | liuyi1@kysec.cn | nieyuanyuan@kysec.cn | | 证书编号：S0790523070002 | 证书编号：S0790124070022 | 证书编号：S0790124050002 | 集采政策持续优化，仿创 pharma 有望估值重塑 集采政策优化基调明确， ...

Investment Rating - The report does not explicitly provide an investment rating for the sleep health industry Core Insights - The sleep health industry is focused on improving and maintaining individual sleep quality, addressing the increasing prevalence of sleep issues, and meeting consumer demand for high-quality sleep solutions driven by technological innovations [4][5][9] - The market is expanding due to factors such as rising consumer awareness of sleep quality, the integration of technology, the aging population, and the evolution of sales models that blend online and offline channels [4][12][29] Industry Overview - The sleep health industry encompasses a wide range of activities and services aimed at improving sleep quality, preventing and treating sleep disorders, and enhancing overall health related to sleep [5][6] - Key segments include sleep monitoring devices, sleep aids, therapeutic services, bedding products, and sleep medications [6][7] Market Demand - The demand for sleep health products is steadily increasing, with a reported sleep disturbance rate of 48.5% among adults in China, highlighting the urgency for effective solutions [10][11] - Women experience a higher sleep disturbance rate (51.1%) compared to men (45.9%), and the rate increases with age, reaching 73.7% among those aged 65 and above [11] Policy Environment - The policy landscape for the sleep health industry is improving, with government initiatives emphasizing the importance of sleep health and supporting the development of related products and services [12][32] - Policies such as the "14th Five-Year Plan for National Health" promote the application of advanced technologies in health services, which is expected to benefit the sleep health sector [32][34] Consumer Behavior - Consumers are increasingly rational in their purchasing decisions, prioritizing product effectiveness and safety, and showing a high acceptance of smart and personalized sleep products [13][20] - The market for smart sleep products, such as smart mattresses and sleep monitoring devices, is growing, with consumers willing to invest in solutions that enhance sleep quality [29][20] Industry Development - The sleep health industry has evolved through various stages, from early research in the 19th century to the current phase characterized by technological advancements and a focus on integrated health solutions [14][18] - The industry is witnessing a shift from traditional product manufacturing to smart, technology-driven solutions that encompass hardware, digital services, and health management [28][29] Competitive Landscape - The competitive landscape is diverse, with traditional companies like Mousse and Xilinmen maintaining significant market positions in bedding products, while new entrants focus on innovative sleep solutions [35][36] - The market is characterized by rapid expansion and transformation, driven by technological advancements and a growing emphasis on comprehensive sleep health solutions [35][36] Market Size and Growth - The sleep health market is expected to continue expanding, with increasing consumer focus on sleep quality and the integration of technology into sleep solutions [29][28] - The market is projected to grow as consumers increasingly invest in sleep health products and services, supported by the rise of the aging population and the blending of online and offline sales channels [29][28]

Group 1 - The Hong Kong stock market for innovative drugs has seen significant gains, with companies like Bohan Bio rising over 17%, and other firms such as Sihuan Pharmaceutical and Sanofi Biotech also experiencing substantial increases [1] - Various ETFs related to innovative drugs have also performed well, with multiple funds rising over 2% and others over 1.5% [1][3] Group 2 - Recent updates from the National Healthcare Security Administration indicate that several new innovative drugs have been rapidly entering hospitals, with a focus on those included in the medical insurance directory by May 2025 [5][6] - Notable drugs showing fast hospital admission growth include those from Kangfang Biotech and Shanghai Yizhong, among others [6] Group 3 - Citigroup's research report highlights a significant increase in market interest in the healthcare sector, particularly in innovative drugs, with expectations for the CXO sector to gain attention due to improved fundamentals and attractive valuations [7] - The report also mentions that WuXi AppTec's revenue for fiscal year 2024 is projected to reach 39.24 billion RMB (approximately 5.4 billion USD), with a growth forecast of 10%-15% for 2025 [7] Group 4 - According to CICC's research, China's innovative drug sector is transitioning into a phase of gradual innovation, gaining international competitiveness [8] - The report emphasizes that the domestic innovative drug industry is expected to reach a turning point by 2025, shifting from capital-driven growth to profit-driven growth [8]

Investment Rating - The report maintains an investment rating of "Leading the Market - A" [9] Core Insights - The report highlights that several newly included innovative drugs in the medical insurance directory are rapidly entering hospitals, with significant growth in the number of drugs entering hospitals by the end of May 2025 compared to April 2025 [2][22] - The report notes that the new drug sector has shown a strong performance, with notable increases in stock prices for companies such as Beihai Kangcheng (114.5%), Frontier Biotech (41.4%), and Junsheng Tai (29.4%) during the week of July 7 to July 13, 2025 [1][18] Summary by Sections Weekly New Drug Market Review - From July 7 to July 13, 2025, the top five companies in the new drug sector by stock price increase were Beihai Kangcheng (114.5%), Frontier Biotech (41.4%), Junsheng Tai (29.4%), Kaituo Pharmaceutical (20.7%), and Yongtai Biotech (20.1%) [1][18] - The top five companies by stock price decrease were Yiming Anke (-19.4%), Shenzhou Cell (-13.4%), Ascentage Pharma (-10.0%), Lepu Biotech (-8.9%), and Rongchang Biotech (-8.8%) [1][18] Key Analysis of the New Drug Industry - The National Medical Insurance Administration updated the hospital admission data for innovative drugs included in the medical insurance directory as of the end of May 2025, indicating rapid hospital admissions for several newly included domestic innovative drugs [2][22] - Notable drugs with fast admission growth included Kangfang Biotech's Cardunilumab and Ivorisumab, Shanghai Yizhong's Paclitaxel Micelle, and Zecjin Pharmaceutical's Recombinant Human Thrombin [2][22] New Drug Approval and Acceptance Status - Four new drug or new indication applications were approved this week, including Ascentage Pharma's Lisatoclax tablets and Zhejiang Tianyuan's quadrivalent influenza virus split vaccine [26][27] - Ten new drug applications were accepted, including Dali Yingjie’s Docetaxel Injection and Zhaoke Pharmaceutical's Atropine Sulfate Eye Drops [26][28] Clinical Application Approval and Acceptance Status - This week, 43 new drug clinical applications were approved, and 20 new drug clinical applications were accepted [4][28]

Summary of JinXin Pharmaceutical Conference Call Company Overview - **Company**: JinXin Pharmaceutical - **Key Product**: Innovative drug Didasin has been launched and included in medical insurance Industry Insights - **Market Performance**: Didasin's sales exceeded 50 million yuan in the first half of 2025, with an expected annual sales of 120-130 million yuan, showing good market performance with a steady increase in sales volume [2][4][18] - **Hospital Coverage**: Didasin is currently available in approximately 470 hospitals, with a target to reach 700 by the end of the year. Monthly shipment volumes in some hospitals have reached 4,000-5,000 boxes [2][7] - **Insomnia Treatment Market**: The insomnia treatment market in China has been dormant for nearly 20 years, but demand is strong. The market capacity was 60 billion yuan before the implementation of generic drug collection, which dropped to 40 billion yuan but has since rebounded to 60 billion yuan [11] Key Developments - **Didasin Sales Growth**: Sales volume increased from about 30,000 boxes in March to over 130,000 boxes in June, with an annual target of 180,000 to 200,000 boxes [2][7] - **Oral RPA Development**: JinXin's oral RPA is in Phase I clinical trials, with good results in lowering LC levels. The company aims to complete Phase I trials and start Phase II within the year [6][14] - **Focus Areas**: JinXin's innovation pipeline focuses on the psychiatric and cardiovascular fields, including treatments for depression, schizophrenia, epilepsy, and Parkinson's disease [3][15] Financial Performance - **Q2 Financials**: The second quarter showed improvement compared to the first quarter, with a revenue decline of about 10% in Q1 due to contract renewals, but this impact has been largely mitigated in Q2 [18] - **Shareholder Returns**: JinXin plans a share buyback of 700 million yuan, reflecting a commitment to investor returns and maintaining a high dividend payout ratio [21] Competitive Landscape - **Didasin's Advantages**: Didasin shows good safety and efficacy across a range of insomnia severity, outperforming other new drugs that primarily target mild cases [12][13] - **Market Dynamics**: The introduction of new drugs is expected to enhance awareness and engagement among doctors and patients, potentially revitalizing the insomnia treatment market [11] Strategic Initiatives - **Pricing Adjustments**: JinXin is gradually adjusting the price differences between hospital and external sales to mitigate economic impacts, with a focus on maintaining stability [17] - **Future Plans**: The company is actively seeking overseas partners for clinical trials and aims to expand its product pipeline in the psychiatric domain [4][14][15] Regulatory Considerations - **Didasin's Classification**: Didasin is classified as a controlled substance, primarily sold in hospitals, with potential future plans to develop lower-dose OTC versions as safety data accumulates [20]

资金面上看，两市主力资金全天净流出143.37亿元，今日有10个行业主力资金净流入，轻工制造行业主 力资金净流入规模居首，该行业今日上涨1.52%，全天净流入资金9.30亿元，其次是房地产行业，日涨 幅为1.68%，净流入资金为9.17亿元。 主力资金净流出的行业有21个，电子行业主力资金净流出规模居首，全天净流出资金44.75亿元，其次 是医药生物行业，净流出资金为34.30亿元，净流出资金较多的还有通信、计算机、机械设备等行业。 医药生物行业今日下跌0.97%，全天主力资金净流出34.30亿元，该行业所属的个股共474只，今日上涨 的有176只，涨停的有6只；下跌的有277只。以资金流向数据进行统计，该行业资金净流入的个股有171 只，其中，净流入资金超5000万元的有5只，净流入资金居首的是联环药业，今日净流入资金1.15亿 元，紧随其后的是宝莱特、联影医疗，净流入资金分别为8373.92万元、7667.30万元。医药生物行业资 金净流出个股中，资金净流出超亿元的有8只，净流出资金居前的有广生堂、长春高新、京新药业，净 流出资金分别为2.28亿元、1.51亿元、1.37亿元。（数据宝） 医药生物行业资金 ...

Group 1 - The U.S. Congress passed the "Big and Beautiful" tax and spending bill, which is controversial due to cuts in federal aid, increased long-term debt, and tax reductions for the wealthy and large corporations [2] - The new tariffs on goods entering the U.S. will range from 10% to 70%, effective August 1 [2] - India plans to impose retaliatory tariffs on the U.S. due to the impact of increased tariffs on automotive exports [2] Group 2 - The U.S. stock market was closed on July 4, with early closures for futures contracts on various commodities [3] - International oil prices saw a slight decline, with WTI crude oil futures at $66.49 per barrel, down 0.76%, and Brent crude at $68.51 per barrel, down 0.42% [3] - The cryptocurrency market weakened, with Bitcoin down over 1%, Ethereum nearly 3%, and Dogecoin over 5% [3] Group 3 - The Ministry of Commerce of China confirmed that the U.S. has taken actions to lift certain trade restrictions on China, including the export of EDA software and ethane [5] - The Ministry of Commerce announced a final ruling on anti-dumping investigations into brandy imports from the EU, with dumping margins identified between 27.7% and 34.9% [6] - China Shipbuilding Industry Corporation's merger with China State Shipbuilding Corporation has been approved, creating the largest publicly listed shipbuilding company globally [8] Group 4 - CATL and Geely have signed a comprehensive strategic cooperation agreement focusing on battery technology and supply chain collaboration [9] - The Ministry of Housing and Urban-Rural Development emphasized the importance of stabilizing the real estate market and implementing targeted policies [21] - The Civil Aviation Administration of China established a leadership group for general aviation and low-altitude economy development [22]

Market Overview - On July 4, A-shares showed mixed performance with the three major indices fluctuating. The total trading volume reached 1.45 trillion yuan, an increase of 121 billion yuan compared to the previous trading day, with over 4,100 stocks declining [1] - Market focus was on stablecoins, digital currencies, and cross-border payment sectors, while banking and gaming sectors strengthened. Energy metals and small metals sectors experienced declines [1] Stock Performance - A total of 39 stocks hit the daily limit up, with 10 stocks achieving consecutive limit ups. The limit up rate was 65% (excluding ST and delisted stocks) [3] - Notable stocks included Chengbang Co., which saw a significant drop after hitting the limit up, while innovative drug concept stock Seli Medical achieved a limit up for the fourth consecutive day [3] Key Stocks and Trading Data - **Shenzhou Cell**: Increased by 16.46% with a trading volume of 20.17 million shares and a total transaction value of 1.63 billion yuan. Institutional net buying amounted to 156 million yuan [18] - **Jingxin Pharmaceutical**: Rose by 10.02% with a trading volume of 8.74 million shares and a total transaction value of 1.49 billion yuan. The company focuses on innovative drugs and medical devices [9][10] - **Hengbao Co.**: Engaged in financial technology and digital currency, with a focus on expanding overseas markets. The company reported overseas revenue of 93.62 million yuan, accounting for 10.37% of total revenue [12] - **Jingbeifang**: Engaged in stablecoin and digital currency sectors, recently signed a strategic cooperation agreement to enhance financial technology innovation [15] Institutional Trading - The top three net buying stocks by institutions were Shenzhou Cell, Hengbao Co., and Nanling Technology, with net purchases of 156 million yuan, 98.35 million yuan, and 91.73 million yuan respectively [6] - The top three net selling stocks were Haoshanghao, Jingbeifang, and Yingfangwei, with net sales of 110 million yuan, 105 million yuan, and 72.72 million yuan respectively [6] Summary of Key Companies - **Jingxin Pharmaceutical**: Focuses on the mental health sector and has a first-class innovative drug expected to be listed in March 2024, with plans to enter the medical insurance payment directory [9][10] - **Hengbao Co.**: Involved in financial technology and digital security, with a focus on digital currency innovation and expanding into overseas markets [12] - **Jingbeifang**: Actively participates in the construction of key digital currency systems for major state-owned banks and aims to innovate in financial technology [15]